AngioDynamics has obtained an FDA green light for its NanoKnife prostate cancer ablation system, designed to precisely target ...
AngioDynamics has won US Food and Drug Administration (FDA) clearance for its NanoKnife system to be used in prostate cancer ...
AngioDynamics received FDA 510(k) clearance for its NanoKnife system for prostate tissue ablation in intermediate-risk ...
AngioDynamics, Inc. (NASDAQ: ANGO), a leading and transformative medical technology company focused on restoring healthy blood flow in the body’s vascular system, expanding cancer treatment options ...
Shares of AngioDynamics hit a 52-week high after the company's NanoKnife System for prostate tissue ablation received regulatory clearance. The stock jumped almost 35% to a high of $9.42 in early ...
Published in Nature Communications, a new study led by the University of Minnesota Medical School and Duke University found ...
Prostate cancer vaccines, including dendritic and peptide types, offer hope for improved treatments, but face hurdles in ...
About 1 in 8 men will get prostate cancer in their lifetime. But a new study concludes an increasing number of men with limited life expectancy are being overtreated for the disease with ...
Prostate cancer, a significant health concern, is projected to rise in India, with cases expected to double by 2040. Family history significantly increases the risk, making vigilant screening crucial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback